Prognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response?

Orphanet Journal of Rare Diseases

Stefano Ferrari³  Piero Picci¹  Marco Gambarotti⁴  Gabriella Gamberi⁵  Stefania Benini⁴  Davide Donati²  Laura Pazzaglia¹  Irene Quattrini¹  Maria Serena Benassi¹  Emanuela Palmerini⁶ 

[1] Laboratory of Experimental Research, Bologna, Italy;Orthopaedic Surgery, Bologna, Italy;Section of Chemotherapy Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, Bologna, Italy;Surgical Pathology, Bologna, Italy;Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy;PROMETEO Laboratory/Section of Chemotherapy, Research, Innovation & Technology (RIT) Department, Istituto Ortopedico Rizzoli, Via Pupilli, 1, 40136, Bologna, Italy

关键词: Predictive factors;    Prognostic factors;    Synovial sarcoma;    Ezrin;    IGFR1;    CXCR4;   

Others  :  1135330
DOI  :  10.1186/s13023-014-0222-5

 received in 2014-09-25, accepted in 2014-12-30,  发布年份 2015

【 摘 要 】

Background

Synovial sarcoma (SS) is a rare tumor, with dismal survival when metastatic. The role of adjuvant chemotherapy is debated. New prognostic and predictive factors are needed.

Methods

We reviewed patients with localized SS; SS18-SSX fusion transcript presence was confirmed by FISH and RT-PCR. Expression of CXCR4, IGF-1R and Ezrin were evaluated by immunohistochemistry.

Results

Tumor samples from 88 SS patients (45 female; 43 male) with median age 37 years (range 11–63) were selected. The size of the lesion was > 5 cm in 68% of patients and 34% of cases presented biphasic histotype. All patients underwent surgery, 56% adjuvant radiotherapy (RT), 65% adjuvant chemotherapy. A positive stain for IGF-1R was detected in 55 patients, with nucleus expression in 21 patients. CXCR4 was expressed in 74 patients, nuclear pattern in 31 patients. 80 SS were positive to Ezrin, 48 had cytoplasmatic location, 32 membrane location. With a median follow-up of 6 years (1–30 years), the 5-year overall survival (OS) was 70% (95% CI 60–81). 5-year OS was 63% (95% CI 41-85%) for patients with positive IGF-1R/nuclear expression, and 73% (95% CI 61-85%; P = 0.05) in negative patients. 5-year OS was 47% (95% CI 27-66%) in patients with positive CXCR4/nuclear staining, and 86% (95% CI 76-96%, P = 0.0003) in negative cases. No survival difference was found according to Ezrin expression. By multivariate analysis, nuclear expression of CXCR4 and IGF-1R was confirmed independent adverse prognostic factor for SS patient survival linked to the use of chemotherapy.

Conclusions

Our findings have important potential implications demonstrating that together with clinical prognostic factors such as radiotherapy and age, CXCR4 and IGF-1R negatively influences survival in patients with localized SS. We believe that further studies addressed to the effects of CXCR4 and IGF-1R inhibitors on cell viability and function are needed to plan new and more appropriate SS treatments.

【 授权许可】

   
2015 Palmerini et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Brennan MF, Singer S, Maki RG, O’Sullivan B: Soft tissue sarcoma. In Cancer Principles and Practice of Oncology. 8th edition. Edited by DeVita VT, Hellmann S, Rosenberg SA. Lippincott Williams and Wilkins, Philadelphia, PA; 2008:1741-94.
• [2]Eilber FC, Dry SM: Diagnosis and management of synovial sarcoma. J Surg Oncol 2008, 97:314-20.
• [3]Fletcher CDM, Unni KK, Mertens F: Pathology and genetics of tumors of soft tissue and bone. IARC Press, Lyon, France; 2002.
• [4]Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M: SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998, 338:153-60.
• [5]Panagopoulos I, Mertens F, Isaksson M, Limon J, Gustafson P, Skytting B, et al.: Clinical impact of molecular and cytogenetic findings in synovial sarcoma. Genes Chromosomes Cancer 2001, 31:362-72.
• [6]Palmerini E, Staals EL, Alberghini M, Zanella L, Ferrari C, Benassi M, et al.: Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer 2009, 115(13):2988-98.
• [7]ESMO/European Sarcoma Network Working Group: Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2012, 23(7):92-9.
• [8]Lewis JJ, Antonescu CR, Leung DHY, Blumberg D, Healey JH, Woodruff JM, et al.: Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 2000, 18:2087-94.
• [9]Spillane AJ, A’Hern R, Judson IR, Fisher C, Thomas JM: Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol 2000, 18:3794-803.
• [10]Trassard M, Le Doussal V, Hacene K, Terrier P, Ranchère D, Guillou L, et al.: Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol 2001, 19:525-34.
• [11]Guillou L, Benhattar J, Bonichon F, Gallagher G, Terrier P, Stauffer E, et al.: Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 2004, 22:4040-50.
• [12]Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, et al.: Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 2004, 101:627-34.
• [13]Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al.: Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 2002, 62:135-40.
• [14]Rosen G, Forscher C, Lowenbraun S, Eilber F, Eckardt J, Holmes C, et al.: Synovial sarcoma: uniform response of metastases to high dose ifosfamide. Cancer 1994, 73:2506-11.
• [15]Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer 2008, 112:1585-91.
• [16]Eilber FC, Brennan MF, Eilber FR, Eckardt JJ, Grobmyer SR, Riedel E, et al.: Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg 2007, 246:105-13.
• [17]Francis P, Namlos HM, Muller C, Edén P, Fernebro J, Berner JM, et al.: Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 2007, 8:73. BioMed Central Full Text
• [18]Nagayama S, Katagiri T, Tsunoda T: Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res 2002, 62(20):5859-66.
• [19]Kim RH, Li BD, Chu QD: The role of chemokine receptor CXCR4 in the biologic behavior of human soft tissue sarcoma. Sarcoma 2011, 2011:593708.
• [20]Oda Y, Tateishi N, Matono H, Matsuura S, Yamamaoto H, Tamiya S, et al.: Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma. Int J Cancer 2009, 124(8):1852-9.
• [21]Tornkvist M, Natalishvili N, Xie Y, Girnita A, D’Arcy P, Brodin B, et al.: Differential roles of SS18–SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth. Biochem Biophys Res Commun 2008, 368:793-800.
• [22]Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O: Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res 1999, 59:3588-91.
• [23]Ferrari S, Zanella L, Alberghini M, Palmerini E, Staals E, Bacchini P: Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma. Pediatr Blood Cancer 2008, 50(4):752-6.
• [24]Lu YJ, Birdsall S, Summersgill B, Smedley D, Osin P, Fisher C, et al.: Dual colour fluorescence in situ hybridization to paraffin-embedded samples to deduce the presence of the der(X)t(X;18)(p11.2;q11.2) and involvement of either the SSX1 or SSX2 gene: a diagnostic and prognostic aid for synovial sarcoma. J Pathol 1999, 187:490-6.
• [25]Sun Y, Gao D, Liu Y, Huang J, Lessnick S, Tanaka S: IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene 2006, 25(7):1042-52.
• [26]Enneking WF, Spanier SS, Goodman MA: Current concepts review. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg 1980, 62-A:1027-30.
• [27]Stanelle EJ, Christison-Lagay ER, Wolden SL, Meyers PA, La Quaglia MP: Pulmonary metastasectomy in pediatric/adolescent patients with synovial sarcoma: an institutional review. Pediatr Surg 2013, 48(4):757-63.
• [28]Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, van der Graaf WT: The insulin-like growth factor system and sarcomas. J Pathol 2009, 217(4):469-82.
• [29]De Bruijn DR, Allander SV, Van Dijk AH, Willemse MP, Thijssen J, van Groningen JJ, et al.: The synovial-sarcoma associated SS18–SSX2 fusion protein induces epigenetic gene (de)regulation. Cancer Res 2006, 66:9474-82.
• [30]Allander SV, Illei PB, Chen Y, Antonescu CR, Bittner M, Ladanyi M, et al.: Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 2002, 161(5):1587-95.
• [31]Friedrichs N, Küchler J, Endl E, Koch A, Czerwitzki J, Wurst P, et al.: Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. J Pathol 2008, 216(4):428-39.
• [32]Sarfstein R, Pasmanik-Chor M, Yeheskel A, Edry L, Shomron N, Warman N, et al.: Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells. J Biol Chem 2012, 287(4):2766-76.
• [33]Gold KA, Kim ES, Liu D, Yuan P, Behrens C, Solis LM, et al.: Prediction of survival in resected non-small cell lung cancer using a protein-expression based risk model: Implications for personalized chemoprevention and therapy. Clin Cancer Res 2014, 20(7):1946-54.
• [34]Asmane I, Watkin E, Alberti L, Duc A, Marec-Berard P, Ray-Coquard I, et al.: Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer 2012, 48(16):3027-35.
• [35]Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG, et al.: A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 2013, 49(1):219-30.
• [36]Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, et al.: Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005, 11:1835-41.
• [37]Yopp AC, Shia J, Butte JM, Allen PJ, Fong Y, Jarnagin WR, et al.: CXCR4 predicts patients outcome and recurrence patters after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2012, 19(Suppl 3):S339-46.
• [38]Bachet JB, Maréchal R, Demetter P, Bonnetain F, Couvelard A, Svrcek M, et al.: Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Ann Oncol 2012, 23(9):2327-35.
• [39]Fanelli MF, Chinen LT, Begnami MD, Costa WL Jr, Fregnami JH, Soares FA, et al.: The influence of transforming growth factor-α, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer. Histopathology 2012, 61(2):153-6.
• [40]D’Alterio C, Portella L, Ottaiano A, Rizzo M, Carteni G, Pignata S, et al.: High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer. Curr Cancer Drug Targets 2012, 12(6):693-702.
• [41]Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al.: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-48.
• [42]Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK: CXCL12 (SDF1-α) -CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 2011, 17:2074-80.
• [43]Weng WH, Ahlén J, Aström K, Lui WO, Larsson C: Prognostic Impact of Immunohistochemical expression of ezrin in highly malignant soft tissue sarcoma. Br J Cancer 1999, 80:1809-14.
• [44]Skytting BT, Bauer HC, Perfekt R, Nilsson G, Larsson O: Ki-67 is strongly prognostic in synovial sarcoma: analysis based on 86 patients from the Scandinavian Sarcoma group register. Clin Cancer Res 2005, 11:6198-204.
• [45]Schneider-Stock R, Onnasch D, Haeckel C, Mellin W, Franke DS, Roessner A: Prognostic significance of p53 gene mutations and p53 protein expression in synovial sarcomas. Virchows Arch 1999, 435:407-12.
• [46]Lagarde P, Przybyl J, Brulard C, Pérot G, Pierron G, Delattre O, et al.: Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol 2013, 31:608-15.